{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:06:20Z","timestamp":1771211180643,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10067-019-04675-2","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T14:02:27Z","timestamp":1563285747000},"page":"177-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["SAPHO: has the time come for tailored therapy?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-2848","authenticated-orcid":false,"given":"Adelaide Sofia Batalha","family":"Figueiredo","sequence":"first","affiliation":[]},{"given":"Ana Lu\u00edsa","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Caetano","sequence":"additional","affiliation":[]},{"given":"Maria Francisca","family":"Moraes-Fontes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"4675_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-3-540-69375-8_77","volume":"8","author":"M-F Kahn","year":"1994","unstructured":"Kahn M-F, Khan MA (1994) The SAPHO syndrome. Baillieres Clin Rheumatol 8:333\u2013362. \nhttps:\/\/doi.org\/10.1007\/978-3-540-69375-8_77","journal-title":"Baillieres Clin Rheumatol"},{"key":"4675_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/14397595.2017.1416733","volume":"28","author":"C Li","year":"2018","unstructured":"Li C, Cao Y, Zhang W (2018) Clinical heterogeneity of SAPHO syndrome: challenge of diagnosis. Mod Rheumatol 28:432\u2013434. \nhttps:\/\/doi.org\/10.1080\/14397595.2017.1416733","journal-title":"Mod Rheumatol"},{"key":"4675_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/rheumatology\/kew015","volume":"55","author":"C Li","year":"2016","unstructured":"Li C, Zuo Y, Wu N, Li L, Li F, Zhang W, Xu W, Zhao X, Jing H, Pan Q, Zhou W, Shi X, Fan Y, Wang J, Liu S, Liu Z, Zhang F, Zeng X, Chen H, Zhang S, Liu J, Qiu G, Wu Z, Dong Z, Zhang W (2016) Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a single centre study of a cohort of 164 patients. Rheumatology (Oxford) 55:1023\u20131030. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kew015","journal-title":"Rheumatology (Oxford)"},{"key":"4675_CR4","doi-asserted-by":"publisher","unstructured":"Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR (2016) SAPHO syndrome: current developments and approaches to clinical treatment. Curr Rheumatol Rep 18. \nhttps:\/\/doi.org\/10.1007\/s11926-016-0583-y","DOI":"10.1007\/s11926-016-0583-y"},{"key":"4675_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/1871528113666140520100402","volume":"13","author":"D Firinu","year":"2014","unstructured":"Firinu D, Murgia G, Lorrai M, Barca M, Peralta M, Manconi P, Giacco S (2014) Biological treatments for SAPHO syndrome: an update. Inflamm Allergy Drug Targets 13:199\u2013205. \nhttps:\/\/doi.org\/10.2174\/1871528113666140520100402","journal-title":"Inflamm Allergy Drug Targets"},{"key":"4675_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.semarthrit.2018.04.003","volume":"48","author":"D Daoussis","year":"2018","unstructured":"Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis SN (2018) Biologics in SAPHO syndrome: a systematic review. Semin Arthritis Rheum 48:618\u2013625. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2018.04.003","journal-title":"Semin Arthritis Rheum"},{"key":"4675_CR7","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","volume":"49","author":"M Colina","year":"2010","unstructured":"Colina M, Pizzirani C, Khodeir M, Falzoni S, Bruschi M, Trotta F, di Virgilio F (2010) Dysregulation of P2X7receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology 49:1416\u20131418. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/keq074","journal-title":"Rheumatology"},{"key":"4675_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","volume":"71","author":"D Wendling","year":"2012","unstructured":"Wendling D, Prati C, Aubin F (2012) Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis 71:1098\u20131100. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2011-200743","journal-title":"Ann Rheum Dis"},{"key":"4675_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1684\/EJD.2016.2854","volume":"26","author":"H Cornillier","year":"2016","unstructured":"Cornillier H, Kervarrec T, Tabareau-Delalande F, Mammou S, Jonville Bera AP, Machet L (2016) Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab. Eur J Dermatol 26:614\u2013615. \nhttps:\/\/doi.org\/10.1684\/EJD.2016.2854","journal-title":"Eur J Dermatol"},{"key":"4675_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jbspin.2017.05.016","volume":"84","author":"D Wendling","year":"2017","unstructured":"Wendling D, Aubin F, Verhoeven F, Prati C (2017) IL-23\/Th17 targeted therapies in SAPHO syndrome. A case series. Jt Bone Spine 84:733\u2013735. \nhttps:\/\/doi.org\/10.1016\/j.jbspin.2017.05.016","journal-title":"Jt Bone Spine"},{"key":"4675_CR11","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.2169\/internalmedicine.8473-16","volume":"56","author":"H Sato","year":"2017","unstructured":"Sato H, Wada Y, Hasegawa E, Nozawa Y, Nakatsue T, Ito T, Kuroda T, Saeki T, Umezu H, Suzuki Y, Nakano M, Narita I (2017) Adult-onset chronic recurrent multifocal osteomyelitis with high intensity of muscles detected by magnetic resonance imaging, successfully controlled with tocilizumab. Intern Med 56:2353\u20132360. \nhttps:\/\/doi.org\/10.2169\/internalmedicine.8473-16","journal-title":"Intern Med"},{"key":"4675_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjd.16071","volume":"179","author":"S Adamo","year":"2018","unstructured":"Adamo S, Nilsson J, Krebs A, Steiner U, Cozzio A, French LE, Kolios AGA (2018) Successful treatment of SAPHO syndrome with apremilast. Br J Dermatol 179:959\u2013962. \nhttps:\/\/doi.org\/10.1111\/bjd.16071","journal-title":"Br J Dermatol"},{"key":"4675_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MD.0000000000011149","volume":"97","author":"Q Yang","year":"2018","unstructured":"Yang Q, Zhao Y, Li C, Luo Y, Hao W, Zhang W (2018) Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Medicine (Baltimore) 97:23\u201326. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000011149","journal-title":"Medicine (Baltimore)"},{"key":"4675_CR14","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/art.10539","volume":"46","author":"AD Wagner","year":"2002","unstructured":"Wagner AD, Andresen J, Jendro MC, H\u00fclsemann JL, Zeidler H (2002) Sustained response to tumor necrosis factor \u03b1-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46:1965\u20131968. \nhttps:\/\/doi.org\/10.1002\/art.10539","journal-title":"Arthritis Rheum"},{"key":"4675_CR15","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.091086","volume":"37","author":"K Ben Abdelghani","year":"2010","unstructured":"Ben Abdelghani K, Dran DG, Gottenberg JE et al (2010) Tumor necrosis factor-\u03b1 blockers in SAPHO syndrome. J Rheumatol 37:1699\u20131704. \nhttps:\/\/doi.org\/10.3899\/jrheum.091086","journal-title":"J Rheumatol"},{"key":"4675_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2340\/00015555-0822","volume":"90","author":"S Arias-Santiago","year":"2010","unstructured":"Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, Fern\u00e1ndez-Pugnaire MA, Ortego-Centeno N (2010) Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol 90:301\u2013302","journal-title":"Acta Derm Venereol"},{"key":"4675_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/1756-185X.12525","volume":"18","author":"S Fujita","year":"2015","unstructured":"Fujita S, Kosaka N, Mito T, Hayashi H, Morita Y (2015) Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis. Int J Rheum Dis 18:476\u2013479. \nhttps:\/\/doi.org\/10.1111\/1756-185X.12525","journal-title":"Int J Rheum Dis"},{"key":"4675_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/ard.61.4.375","volume":"61","author":"I Olivieri","year":"2002","unstructured":"Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F (2002) Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 61:375\u2013376","journal-title":"Ann Rheum Dis"},{"key":"4675_CR19","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaad.2004.09.006","volume":"52","author":"M Iqbal","year":"2005","unstructured":"Iqbal M, Kolodney MS (2005) Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 52:S118\u2013S120. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2004.09.006","journal-title":"J Am Acad Dermatol"},{"key":"4675_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/rheumatology\/kei221","volume":"45","author":"A Massara","year":"2006","unstructured":"Massara A, Cavazzini PL, Trotta F (2006) In SAPHO syndrome anti-TNF-\u03b1 therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45:730\u2013733. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/kei221","journal-title":"Rheumatology"},{"key":"4675_CR21","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10067-007-0767-y","volume":"27","author":"F Sabugo","year":"2008","unstructured":"Sabugo F, Liberman C, Niedmann JP, Soto L, Cuchacovich M (2008) Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol 27:533\u2013535. \nhttps:\/\/doi.org\/10.1007\/s10067-007-0767-y","journal-title":"Clin Rheumatol"},{"key":"4675_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.semarthrit.2007.08.004","volume":"37","author":"C Moll","year":"2008","unstructured":"Moll C, Hern\u00e1ndez MV, Ca\u00f1ete JD, G\u00f3mez-Puerta JA, Soriano A, Collado A, Sanmart\u00ed R (2008) Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 37:299\u2013306. \nhttps:\/\/doi.org\/10.1016\/j.semarthrit.2007.08.004","journal-title":"Semin Arthritis Rheum"},{"key":"4675_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr.10.2008.1145","volume":"2009","author":"J Fruehauf","year":"2009","unstructured":"Fruehauf J, Cierny-Modr\u00e8 B, El-Shabrawi Caelen L et al (2009) Response to infliximab in SAPHO syndrome. BMJ Case Rep 2009:1\u20139. \nhttps:\/\/doi.org\/10.1136\/bcr.10.2008.1145","journal-title":"BMJ Case Rep"},{"key":"4675_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10067-010-1476-5","volume":"29","author":"I Castellv\u00ed","year":"2010","unstructured":"Castellv\u00ed I, Bonet M, Narv\u00e1ez JA, Molina-Hinojosa JC (2010) Successful treatment of SAPHO syndrome with adalimumab: a case report. Clin Rheumatol 29:1205\u20131207. \nhttps:\/\/doi.org\/10.1007\/s10067-010-1476-5","journal-title":"Clin Rheumatol"},{"key":"4675_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2340\/00015555-0895","volume":"90","author":"J Vilar-Alejo","year":"2010","unstructured":"Vilar-Alejo J, Dehesa L, De La Rosa-del Rey P et al (2010) SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm Venereol 90:531\u2013532. \nhttps:\/\/doi.org\/10.2340\/00015555-0895","journal-title":"Acta Derm Venereol"},{"key":"4675_CR26","first-page":"185","volume":"69","author":"A de Souza","year":"2011","unstructured":"de Souza A, Solomon GE, Strober BE (2011) SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis 69:185\u2013187","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"4675_CR27","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00296-011-1916-9","volume":"32","author":"LL Zhang","year":"2012","unstructured":"Zhang LL, Zhao JX, Liu XY (2012) Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study. Rheumatol Int 32:1963\u20131965. \nhttps:\/\/doi.org\/10.1007\/s00296-011-1916-9","journal-title":"Rheumatol Int"},{"key":"4675_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/11593250-000000000-00000","volume":"13","author":"S Garcovich","year":"2012","unstructured":"Garcovich S, Amelia R, Magarelli N, Valenza V, Amerio P (2012) Long-term treatment of severe SAPHO syndrome with adalimumab. Am J Clin Dermatol 13:55\u201359. \nhttps:\/\/doi.org\/10.2165\/11593250-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"4675_CR29","first-page":"444","volume":"70","author":"LT Burgemeister","year":"2012","unstructured":"Burgemeister LT, Baeten DLP, Tas SW (2012) Biologics for rare inflammatory diseases: TNF blockade in the SAPHO syndrome. Neth J Med 70:444\u2013449","journal-title":"Neth J Med"},{"issue":"jan25 1","key":"4675_CR30","doi-asserted-by":"publisher","first-page":"bcr2012007161","DOI":"10.1136\/bcr-2012-007161","volume":"2013","author":"S. L. Hampton","year":"2013","unstructured":"Hampton SL, Youssef H (2013) Successful treatment of resistant SAPHO syndrome with anti-TNF therapy. BMJ Case Rep:2012\u20132014. \nhttps:\/\/doi.org\/10.1136\/bcr-2012-007161","journal-title":"Case Reports"},{"key":"4675_CR31","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1007\/s10620-013-2653-6","volume":"58","author":"JE Naves","year":"2013","unstructured":"Naves JE, Cabr\u00e9 E, Ma\u00f1osa M, Grados D, Oliv\u00e9 A, Dom\u00e8nech E (2013) A systematic review of SAPHO syndrome and inflammatory bowel disease association. Dig Dis Sci 58:2138\u20132147. \nhttps:\/\/doi.org\/10.1007\/s10620-013-2653-6","journal-title":"Dig Dis Sci"},{"key":"4675_CR32","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s10067-013-2251-1","volume":"32","author":"BK Kundu","year":"2013","unstructured":"Kundu BK, Naik AK, Bhargava S, Srivastava D (2013) Diagnosing the SAPHO syndrome: a report of three cases and review of literature. Clin Rheumatol 32:1237\u20131243. \nhttps:\/\/doi.org\/10.1007\/s10067-013-2251-1","journal-title":"Clin Rheumatol"},{"key":"4675_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pmrj.2013.08.610","volume":"6","author":"CH Kim","year":"2014","unstructured":"Kim CH, Kadhim S, Julien C (2014) Treatment of pain in SAPHO (synovitis, acne, Pustulosis, hyperostosis, and osteitis) syndrome. PM R 6:92\u201395. \nhttps:\/\/doi.org\/10.1016\/j.pmrj.2013.08.610","journal-title":"PM R"},{"key":"4675_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5152\/eurjrheumatol.2014.037","volume":"1","author":"FE Abourazzak","year":"2014","unstructured":"Abourazzak FE, Hachimi H, Kadi N, Berrada K, Tizniti S, Harzy T (2014) Etanercept in the treatment of SAPHO syndrome: which place? Eur J Rheumatol 1:125\u2013128. \nhttps:\/\/doi.org\/10.5152\/eurjrheumatol.2014.037","journal-title":"Eur J Rheumatol"},{"key":"4675_CR35","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.jcms.2014.09.004","volume":"42","author":"A Mar\u00ed","year":"2014","unstructured":"Mar\u00ed A, Morla A, Melero M, Schiavone R, Rodr\u00edguez J (2014) Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with anti-TNF therapy. Systematic review. J Cranio-Maxillofac Surg 42:1990\u20131996. \nhttps:\/\/doi.org\/10.1016\/j.jcms.2014.09.004","journal-title":"J Cranio-Maxillofac Surg"},{"key":"4675_CR36","first-page":"180","volume":"22","author":"B Ani\u0107","year":"2014","unstructured":"Ani\u0107 B, Padjen I, Mayer M et al (2014) Clinical features of the SAPHO syndrome and their role in choosing the therapeutic approach: report of four patients and review of the literature. Acta Dermatovenerol Croat 22:180\u2013188","journal-title":"Acta Dermatovenerol Croat"},{"key":"4675_CR37","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/ijd.12675","volume":"54","author":"L-C S\u00e1ez-Mart\u00edn","year":"2015","unstructured":"S\u00e1ez-Mart\u00edn L-C, G\u00f3mez-Castro S, Rom\u00e1n-Curto C, Palacios-\u00c1lvarez I, Fern\u00e1ndez-L\u00f3pez E (2015) Etanercept in the treatment of SAPHO syndrome. Int J Dermatol 54:e206\u2013e208. \nhttps:\/\/doi.org\/10.1111\/ijd.12675","journal-title":"Int J Dermatol"},{"key":"4675_CR38","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00296-015-3263-8","volume":"35","author":"Y Kamata","year":"2015","unstructured":"Kamata Y, Minota S (2015) Successful treatment of a patient with SAPHO syndrome with certolizumab pegol. Rheumatol Int 35:1607\u20131608. \nhttps:\/\/doi.org\/10.1007\/s00296-015-3263-8","journal-title":"Rheumatol Int"},{"key":"4675_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.joen.2015.04.005","volume":"41","author":"E Cotti","year":"2015","unstructured":"Cotti E, Careddu R, Schirru E, Marongiu S, Barca MP, Manconi PE, Mercuro G (2015) A case of SAPHO syndrome with endodontic implications and treatment with biologic drugs. J Endod 41:1565\u20131570. \nhttps:\/\/doi.org\/10.1016\/j.joen.2015.04.005","journal-title":"J Endod"},{"key":"4675_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jfma.2013.10.001","volume":"114","author":"YS Su","year":"2015","unstructured":"Su YS, Chang CH (2015) SAPHO syndrome associated with acne conglobata successfully treated with etanercept. J Formos Med Assoc 114:562\u2013564. \nhttps:\/\/doi.org\/10.1016\/j.jfma.2013.10.001","journal-title":"J Formos Med Assoc"},{"key":"4675_CR41","first-page":"62","volume":"5","author":"L Zhang","year":"2016","unstructured":"Zhang L, Gao Z (2016) Etanercept in the treatment of refractory SAPHO syndrome. Am J Clin Exp Immunol 5:62\u201366","journal-title":"Am J Clin Exp Immunol"},{"key":"4675_CR42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.reuma.2015.11.016","volume":"13","author":"L Mateo","year":"2017","unstructured":"Mateo L, Sanint J, Rodr\u00edguez Muguruza S, Mart\u00ednez Morillo M, P\u00e9rez Andr\u00e9s R, Domenech Puigcerver S (2017) Lesi\u00f3n osteol\u00edtica cervical como presentaci\u00f3n del s\u00edndrome SAPHO. Reumatol Clin 13:44\u201347. \nhttps:\/\/doi.org\/10.1016\/j.reuma.2015.11.016","journal-title":"Reumatol Clin"},{"key":"4675_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00296-012-2606-y","volume":"34","author":"B Ani\u0107","year":"2014","unstructured":"Ani\u0107 B, Padjen I, Bare\u0161i\u0107 M, Te\u017eak S (2014) The lobster sign in SAPHO syndrome: unusually extensive osteitis of the anterior chest wall partially responsive to infliximab. Rheumatol Int 34:281\u2013282. \nhttps:\/\/doi.org\/10.1007\/s00296-012-2606-y","journal-title":"Rheumatol Int"},{"key":"4675_CR44","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s10067-017-3751-1","volume":"36","author":"F Cianci","year":"2017","unstructured":"Cianci F, Zoli A, Gremese E, Ferraccioli G (2017) Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. Clin Rheumatol 36:2151\u20132158. \nhttps:\/\/doi.org\/10.1007\/s10067-017-3751-1","journal-title":"Clin Rheumatol"},{"key":"4675_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ijd.13740","volume":"57","author":"DA Vekic","year":"2018","unstructured":"Vekic DA, Woods J, Lin P, Cains GD (2018) SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol 57:10\u201318. \nhttps:\/\/doi.org\/10.1111\/ijd.13740","journal-title":"Int J Dermatol"},{"key":"4675_CR46","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1002\/art.24781","volume":"60","author":"R Axmann","year":"2009","unstructured":"Axmann R, B\u00f6hm C, Kr\u00f6nke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60:2747\u20132756. \nhttps:\/\/doi.org\/10.1002\/art.24781","journal-title":"Arthritis Rheum"},{"key":"4675_CR47","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bjd.12150","volume":"168","author":"C Morales-M\u00fanera","year":"2013","unstructured":"Morales-M\u00fanera C, Vilarrasa E, Puig L (2013) Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 168:820\u2013824","journal-title":"Br J Dermatol"},{"key":"4675_CR48","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","volume":"75","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Puig L, Gottlieb AB, Ritchlin C, You Y, Li S, Song M, Randazzo B, Rahman P, McInnes IB (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2). Ann Rheum Dis 75:1984\u20131988","journal-title":"Ann Rheum Dis"},{"key":"4675_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10067-018-4083-5","volume":"38","author":"C Li","year":"2019","unstructured":"Li C, Wu X, Cao Y, Zeng Y, Zhang W, Zhang S, Liu Y, Jin H, Zhang W, Li L (2019) Paradoxical skin lesions induced by anti-TNF-\u03b1 agents in SAPHO syndrome. Clin Rheumatol 38:53\u201361. \nhttps:\/\/doi.org\/10.1007\/s10067-018-4083-5","journal-title":"Clin Rheumatol"},{"key":"4675_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","volume":"18","author":"P Sarzi-Puttini","year":"2019","unstructured":"Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F (2019) Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev 18:583\u2013592. \nhttps:\/\/doi.org\/10.1016\/j.autrev.2018.12.009","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04675-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04675-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T23:28:35Z","timestamp":1594769315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04675-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4675"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04675-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"22 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Both patients gave informed consent for the publication of their case report and related images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}